Topic: vaccine manufacturing
Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.
Amgen pays $2.7 billion for a 20.5% stake in BeiGene. AstraZeneca tightens its ties to China as China approves a controversial Alzheimer's drug.
Takeda's rare disease sales dropped sharply. Astellas teamed with Pandion on Type 1 diabetes. Shanghai's I-Mab filed for a $100 million Nasdaq IPO.
The U.S. is seeing a spike in measles cases, but Merck, the sole producer of the measles vaccine for the U.S., says it has production in hand.
A former deputy director of the old China FDA has been handed to the prosecutors over suspected duty-related crimes.
Sun Pharma drops to six-year low; Takeda looks to sell emerging markets products; Immunochina raises $20 million for CAR-T push.
WuXi Biologics is forming a human vaccine-focused CDMO joint venture with local veterinary vaccine firm Shanghai Hile Bio-Technology.
Based in Oxford and slated to open in 2022, the center will focus on creating rapid, cost-effective ways of developing and manufacturing vaccines.
Samsung BioLogics faces potential delisting; Merck will increase Gardasil supply to China; Chinese officials mulls new regulation for vaccine.
Merck is increasing its HPV vaccine production capacity, but it still won't be enough to meet the full demand in China, a company spokesperson said.